Alnylam Pharmaceuticals (ALNY) Accounts Payables (2009 - 2026)

Alnylam Pharmaceuticals' Accounts Payables history runs 18 years deep, the most recent figure standing at $126.6 million for Q1 2026.

• Quarterly Accounts Payables rose 30.01% year-over-year to $126.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $126.6 million (up 30.01% YoY) and the FY2025 annual result came in at $115.7 million, up 30.88% from the prior year.
• Accounts Payables was $126.6 million for Q1 2026 at Alnylam Pharmaceuticals, up from $115.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $126.6 million in Q1 2026 and bottomed at $40.6 million in Q3 2022.
• A 5-year average of $80.5 million and a median of $74.0 million in 2024 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 82.0% in 2023, while the deepest fall reached 43.4% in 2023.
• Alnylam Pharmaceuticals' Accounts Payables stood at $98.1 million in 2022, then slumped by 43.4% to $55.5 million in 2023, then surged by 59.25% to $88.4 million in 2024, then surged by 30.88% to $115.7 million in 2025, then rose by 9.43% to $126.6 million in 2026.
• Business Quant data shows ALNY's Accounts Payables at $126.6 million in Q1 2026, $115.7 million in Q4 2025, and $117.6 million in Q3 2025.